Article

DALK preferred over PK

Deep anterior lamellar keratoplasty is the procedure of choice for treating patients with keratoconus and corneal scarring, according to Deepinder Dhaliwal, MD.

Chicago-Deep anterior lamellar keratoplasty (DALK) is the procedure of choice for treating patients with keratoconus and corneal scarring, according to Deepinder Dhaliwal, MD.

“We have come to a revolution in corneal transplantation and are in the era of selective keratoplasty, with only transplantation or removal of diseased corneal layers,” said Dr. Dhaliwal, associate professor, Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh.

“We do not need to do the penetrating keratoplasty (PK) of yesteryear for our patients anymore,” she said. “Endothelial keratoplasty has become the standard of care. Our patients are at a disservice if they are not offered this procedure.”

The advantages of DALK over PK are numerous, most importantly, the long-term viability of the graft endothelium; the endothelial cell count does not decrease as in PK.

In addition, there is no blinding endothelial rejection because the host Descemet’s membrane and endothelium are preserved, less steroid exposure, suture removal is earlier with DALK resulting in faster visual rehabilitation, PK can be performed later if the vision remains suboptimal, and DALK is a closed eye surgery, with the globe more stable intraoperatively and postoperatively, Dr. Dhaliwal explained.

The downsides of DALK include the potential for interface scarring and reduced visual clarity, the procedure is technically challenging, and Descemet’s membrane can be perforated.

Dr. Dhaliwal’s pearls for DALK include putting some small bubbles in the anterior chamber before injecting the big bubble.

“This is incredibly helpful to me to understand what is happening,” she said. She likes Fogla instruments, specifically, a dissector for creating a channel and a blunt cannula with the air port on the back side for insertion into the channel through which air can be injected.

She also puts a cohesive viscoelastic over the top before popping the big bubble to prevent a rapid escape of air. Viscodissection before removing the residual stroma is helpful, she noted.

For more articles in this issue of Ophthalmology Times Conference Briefclick here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.